Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once vs twice daily prednisolone dosing and blood glucose in ANCA-associated vasculitis
2024-516141-39-00Phase 4Authorised
- Sponsor
- Medical University of Graz
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of prednisolone in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and crescentic glomerulonephritis (RPGN) (2 arms), sponsored by Medical University of Graz. Primary endpoint: Mean time in target range 70-180 mg/dL by blinded continuous glucose monitoring. Planned start Nov 2024; status: authorised.
02
Drugs
prednisolone
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)crescentic glomerulonephritis (RPGN)
Beyond the preview
Go deeper on 2024-516141-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516141-39-00.